AU Patent

AU2018200316A1 — Formulations of enzalutamide

Assigned to Astellas Pharma Inc · Expires 2018-02-08 · 8y expired

What this patent protects

Abstract The present invention provides amorphous enzalutamide, formulations of amorphous enzalutamide and their use for treating hyper-proliferative disorders.

USPTO Abstract

Abstract The present invention provides amorphous enzalutamide, formulations of amorphous enzalutamide and their use for treating hyper-proliferative disorders.

Drugs covered by this patent

Patent Metadata

Patent number
AU2018200316A1
Jurisdiction
AU
Classification
—
Expires
2018-02-08
Drug substance claim
No
Drug product claim
No
Assignee
Astellas Pharma Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.